Outcomes | Anticipated absolute effects (95% CI) | Relative effect (95% CI) | № of participants (studies) | Certainty of the evidence (GRADE) | Comments | |
---|---|---|---|---|---|---|
Risk with placebo | Risk with active durg | |||||
Eptinezumab 100 mg quarterly | ||||||
Monthly migraine days | The mean monthly migraine days was −5.6 days | Mean 2.1 days fewer (2.9 fewer to 1.3 fewer) | 956 (2 RCTs) | ⨁⨁⨁⨁ High | Eptinezumab likely results in a reduction in monthly migraine days. | |
> 50% responder rate | 39.6 per 100 | 57.0 per 100 (50.4 to 64.2) | 0.17 (0.11 to 0.24) | 956 (2 RCTs) | ⨁⨁⨁⨁ High | Eptinezumab likely results in an increase in > 50% responder rate. |
Days with acute medication use | The mean reduction in days with acute medication use was −1.9 | Mean 1.2 days fewer (1.7 fewer to 0.6 fewer) | 722 (1 RCT) | ⨁⨁⨁○ Moderatea | Eptinezumab likely results in a reduction of days with acute medication use | |
Eptinezumab 300 mg quarterly | ||||||
Monthly migraine days | The mean monthly migraine days was – 5.6 days | Mean 2.6 days fewer (3.3 fewer to 1.9 fewer) | 946 (2 RCTs) | ⨁⨁⨁⨁ High | Eptinezumab likely results in a slight reduction in monthly migraine days. | |
> 50% responder rate | 39.6 per 100 | 60.3 per 100 (53.5 to 67.8) | 0.21 (0.15 to 0.27) | 946 (2 RCTs) | ⨁⨁⨁⨁ High | Eptinezumab likely results in an increase in > 50% responder rate. |
Days with acute medication use | The mean reduction in days with acute medication use was −1.9 | Mean 1.4 days fewer (1.9 fewer to 0.9 fewer) | 716 (1 RCT) | ⨁⨁⨁○ Moderatea | Eptinezumab likely results in a reduction of days with acute medication use | |
Erenumab 70 mg monthly | ||||||
Monthly migraine days | The mean monthly migraine days was −4.0 days | Mean 2.2 days fewer (3.1 fewer to 1.2 fewer) | 571 (2 RCTs) | ⨁⨁⨁⨁ High | Erenumab likely results in a reduction in monthly migraine days. | |
> 50% responder rate | 23.0 per 100 | 40.0 per 100 (31.4 to 50.0) | 0.16 (0.08 to 0.25) | 469 (1 RCT) | ⨁⨁⨁○ Moderatea | Erenumab likely results in an increase in > 50% responder rate. |
Days with acute medication use | The mean reduction in days with acute medication use was −1.6 | Mean 1.9 fewer (2.6 fewer to 1.1 fewer) | 469 (1 RCT) | ⨁⨁⨁○ Moderatea | Erenumab likely results in a reduction of days with acute medication use | |
Erenumab 140 mg monthly | ||||||
Monthly migraine days | The mean monthly migraine days was −4.2 days | Mean 2.5 days fewer (3.5 fewer to 1.4 fewer) | 468 (1 RCT) | ⨁⨁⨁○ Moderatea | Erenumab likely results in a reduction in monthly migraine days. | |
> 50% responder rate | 23.0 per 100 | 41.0 per 100 (32.5 to 51.5) | 0.18 (0.09 to 0.26) | 468 (1 RCT) | ⨁⨁⨁○ Moderatea | Erenumab likely results in an increase in > 50% responder rate. |
Days with acute medication use | The mean reduction in days with acute medication use was −1.6 | Mean 2.6 fewer (3.3 fewer to 1.8 fewer) | 468 (1 RCT) | ⨁⨁⨁○ Moderatea | Erenumab likely results in a reduction of days with acute medication use | |
Fremanezumab 225 mg monthly | ||||||
Monthly migraine days | The mean monthly migraine days was −2.2 days | Mean 2.6 days fewer (3.3 fewer to 2.0 fewer) | 1463 (4 RCTs) | ⨁⨁⨁○ Moderateb | Fremanezumab likely results in a reduction in monthly migraine days. | |
> 50% responder rate | 18.4 per 100 | 39.0 per 100 (34.4 to 44.2) | 0.20 (0.16 to 0.25) | 1298 (3 RCTs) | ⨁⨁⨁○ Moderateb | Fremanezumab likely results in an increase in > 50% responder rate. |
Days with acute medication use | The mean reduction in days with acute medication use was −2.1 | Mean 1.9 fewer (2.6 fewer to 1.3 fewer) | 1123 (2 RCT) | ⨁⨁○○ Lowa,b | Fremanezumab likely results in a reduction of days with acute medication use | |
Fremanezumab 675 mg quarterly | ||||||
Monthly migraine days | The mean monthly migraine days was −2.2 days | Mean 2.2 days fewer (2.9 fewer to 1.5 fewer) | 1461 (3 RCTs) | ⨁⨁⨁⨁ High | Fremanezumab likely results in a reduction in monthly migraine days. | |
> 50% responder rate | 16.4 per 100 | 34.8 per 100 (30.1 to 40.0) | 0.18 (0.13 to 0.23) | 1125 (2 RCTs) | ⨁⨁⨁○ Moderatea | Fremanezumab likely results in an increase in > 50% responder rate. |
Days with acute medication use | The mean reduction in days with acute medication use was −2.1 | Mean 1.7 fewer (2.4 fewer to 1.0 fewer) | 1125 (2 RCT) | ⨁⨁⨁○ Moderatea | Fremanezumab likely results in a reduction of days with acute medication use | |
Galcanezumab 120 mg monthly (240 mg loading dose) | ||||||
Monthly migraine days | The mean monthly migraine days was −2.5 days | Mean 2.6 days fewer (3.5 fewer to 1.6 fewer) | 1004 (2 RCTs) | ⨁⨁⨁⨁ High | Galcanezumab likely results in a reduction in monthly migraine days. | |
> 50% responder rate | 14.4 per 100 | 28.5 per 100 (23.3 to 34.5) | 0.15 (0.09 to 0.20) | 1004 (2 RCTs) | ⨁⨁⨁⨁ High | Galcanezumab likely results in an increase in > 50% responder rate. |
Days with acute medication use | The mean reduction in days with acute medication use was −2.1 | Mean 2.8 fewer (3.7 fewer to 2.0 fewer) | 1004 (2 RCTs) | ⨁⨁⨁⨁ High | Galcanezumab likely results in a reduction of days with acute medication use |